{"name":"Erin McCreary","slug":"erin-mccreary","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"Lilly Bamlanivimab + Etesevimab","genericName":"Lilly Bamlanivimab + Etesevimab","slug":"lilly-bamlanivimab-etesevimab","indication":"COVID-19 (mild to moderate disease in high-risk patients)","status":"marketed"},{"name":"Regeneron Casirivimab + Imdevimab","genericName":"Regeneron Casirivimab + Imdevimab","slug":"regeneron-casirivimab-imdevimab","indication":"COVID-19 (mild to moderate disease in non-hospitalized patients at high risk for progression to severe disease)","status":"marketed"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Lilly Bamlanivimab","genericName":"Lilly Bamlanivimab","slug":"lilly-bamlanivimab","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Lilly Bamlanivimab","genericName":"Lilly Bamlanivimab","slug":"lilly-bamlanivimab","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"Lilly Bamlanivimab + Etesevimab","genericName":"Lilly Bamlanivimab + Etesevimab","slug":"lilly-bamlanivimab-etesevimab","phase":"marketed","mechanism":"Bamlanivimab and etesevimab are monoclonal antibodies that bind to the SARS-CoV-2 spike protein to neutralize the virus and prevent infection.","indications":["COVID-19 (mild to moderate disease in high-risk patients)"],"catalyst":""},{"name":"Regeneron Casirivimab + Imdevimab","genericName":"Regeneron Casirivimab + Imdevimab","slug":"regeneron-casirivimab-imdevimab","phase":"marketed","mechanism":"This combination of two monoclonal antibodies binds to the SARS-CoV-2 spike protein to neutralize the virus and prevent infection of human cells.","indications":["COVID-19 (mild to moderate disease in non-hospitalized patients at high risk for progression to severe disease)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiswFBVV95cUxPV2tFTi16eVpiUzk3LTVxTVBMN1NHQm5xenlISlZvZ0ZUMXc5bmxpZldrWDFSYzB1VDE4TGVWUmJpQmxMcmNIcE5UQTVhSG5IeHpIdkZFRncyZ19CcFZTYzIwVzd6b1ZTOUI0b1Y1VGYzZmxBUzd0R0hzX2U3NVRQUU8tTDNCclVURmdmd3hFcGYxUjBqc0d4dXdRQkhtb3JXMjRIQnI3czdCZ3daSzM3V1RkVQ?oc=5","date":"2021-12-07","type":"pipeline","source":"Inquirer.com","summary":"UPMC tests easier, quicker way to give monoclonal antibodies for COVID-19 - Inquirer.com","headline":"UPMC tests easier, quicker way to give monoclonal antibodies for COVID-19","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"marketed":3},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}